GlassScriptPhysician profile
Sami Saba
NPI 1932491339
$935.17
in general payments reported to CMS, 2019-2025
19 companies · $698 in 2025
The $698 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.20 · 2021: $24.95 · 2024: $116 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $814.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Argenx US, INC. | $164.73 | 2024-2025 | Vyvgart, Vyvgart Hytrulo |
| Alexion Pharmaceuticals, INC. | $141.89 | 2025 | Ultomiris |
| Biogen, INC. | $103.20 | 2024-2025 | Tysabri, Vumerity, Spinraza |
| Csl Behring | $99.95 | 2019-2025 | Hizentra |
| Genentech USA, INC. | $91.64 | 2025 | Ocrevus Zunovo |
| Abbvie INC. | $63.40 | 2024-2025 | |
| Catalyst Pharmaceuticals, INC. | $28.10 | 2025 | |
| Ge Healthcare | $28.01 | 2025 | |
| Abbott Laboratories | $24.97 | 2024 | Infinity |
| Misonix INC | $24.95 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $24.35 | 2025 | Dojolvi |
| Pfizer INC. | $21.35 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $19.85 | 2019 | |
| Neurocrine Biosciences, INC. | $18.45 | 2024 | Ingrezza |
| Ucb, INC. | $18.17 | 2025 | Rystiggo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lundbeck LLC | $16.90 | 2025 | Vyepti |
| Tanabe Pharma America, INC. | $16.29 | 2025 | Radicava |
| Astrazeneca Pharmaceuticals LP | $15.18 | 2025 | |
| Alnylam Pharmaceuticals INC. | $13.79 | 2025 | Onpattro |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sami Saba listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.